F-1/A: Evaxion Biotech Files Amendment No. 2 to Form F-1 Registration Statement

Evaxion Biotech A/S files an amendment to its Form F-1 registration statement, primarily to include an updated exhibit related to an engagement agreement with H.C. Wainwright & Co., LLC.

Summary

• Evaxion Biotech A/S filed Amendment No. 2 to its Registration Statement on Form F-1.
• The amendment primarily includes Exhibit 1.1, related to the engagement agreement with H.C. Wainwright & Co., LLC.
• The company has agreed to indemnify its board members, executive management, and employees under certain conditions, with a limit of DKK 534.5 million per claim per person.
• In 2022, Evaxion completed a private placement with Lincoln Park Capital Fund, LLC, potentially allowing them to sell up to $40 million of ordinary shares represented by American Depositary Shares (ADS).
• In December 2023, Evaxion entered into purchase agreements for a private placement of 9,726,898 ordinary shares represented by ADSs and warrants, raising approximately $5.3 million with potential additional $6.8 million upon warrant exercise.
• MSD, a subsidiary of Merck Inc., participated in the Private Placement accounting for some 25% of the full offering amount.
• The engagement agreement with H.C. Wainwright & Co., LLC, dated September 27, 2023, appoints them as the exclusive underwriter, agent, or advisor for any offering of Evaxion's securities.
• H.C. Wainwright & Co., LLC will receive a cash fee of 7.5% of the aggregate gross proceeds raised in each offering.
• H.C. Wainwright & Co., LLC will receive warrants equal to 5.0% of the aggregate number of shares of common stock placed in each offering, with an exercise price equal to 135% of the offering price per share.
• H.C. Wainwright & Co., LLC will receive $25,000 for non-accountable expenses (to be increased to $35,000 in case a legal work with respect to a public Offering is initiated or a public Offering is consummated), up to $50,000 for fees and expenses of legal counsel and other out-of-pocket expenses (to be increased to $100,000 in case a legal work with respect to a public Offering is initiated or a public Offering is consummated), and the fees and expenses of a local legal counsel, if such legal counsel is retained by Wainwright for an Offering (not to exceed $50,000).

Sentiment

Score: 6

Explanation: The document is primarily a regulatory filing related to financing activities. While the successful private placement is a positive sign, the need for ongoing capital raising suggests potential financial challenges. The sentiment is neutral to slightly positive.

Positives

• The participation of MSD in the private placement demonstrates confidence in Evaxion's potential.
• The engagement of H.C. Wainwright & Co., LLC, as an exclusive underwriter, agent, or advisor could facilitate future financing opportunities.
• The company has secured $5.3 million in gross proceeds from the Private Placement, with up to an additional $6.8 million of gross proceeds upon cash exercise of the Warrants.

Negatives

• The company's reliance on private placements and potential future offerings suggests a need for ongoing capital raising.
• The indemnification of board members and executive management, while common, could expose the company to financial risks.
• The potential voiding of indemnification under Danish law adds uncertainty.

Risks

• The success of future offerings is subject to market conditions.
• The company's indemnification agreements could be deemed unenforceable under certain circumstances.
• The company's reliance on H.C. Wainwright & Co., LLC, as an exclusive underwriter, agent, or advisor could limit its options for future financing.

Future Outlook

The document outlines the company's ongoing efforts to secure financing and prepare for potential future offerings, but does not provide specific forward-looking statements or guidance.

Industry Context

The document reflects the common practice of biotech companies to raise capital through private placements and potential public offerings to fund research and development activities. The engagement of an underwriter like H.C. Wainwright & Co., LLC, is typical for companies seeking to access capital markets.

Comparison to Industry Standards

• The terms of the engagement agreement with H.C. Wainwright & Co., LLC, including the cash fee and warrant coverage, are generally within the range of industry standards for similar transactions involving small-cap biotech companies.
• The private placement structure, including the participation of institutional investors and company management, is a common approach for raising capital in the biotech sector.
• Comparable companies that have utilized similar financing strategies include [hypothetical company A] and [hypothetical company B], which have also engaged underwriters and conducted private placements to fund their operations.

Stakeholder Impact

• Shareholders may experience dilution from the issuance of new shares and warrants.
• Employees may benefit from the company's ability to fund its operations and research programs.
• The company's creditors may be impacted by changes in its financial position.

Next Steps

• The company will continue to work with H.C. Wainwright & Co., LLC, to explore potential financing opportunities.
• The company will monitor market conditions and assess the feasibility of future offerings.
• The company will continue to execute its research and development programs.

Key Dates

Keywords

Evaxion Biotech, Registration Statement, Private Placement, H.C. Wainwright, Securities, Offering, Warrants, Indemnification, Lincoln Park, MSD